Patents by Inventor Hans Wallberg
Hans Wallberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11845725Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-?-lactamase inhibitors.Type: GrantFiled: September 16, 2022Date of Patent: December 19, 2023Assignee: INFEX Therapeutics LimitedInventors: Ian Cooper, David Orr, Andrew Wilkinson, Jonathan Finlayson, Adam Bunt, Pia Appelqvist, Hans Wallberg, Fredrik Wångsell
-
Publication number: 20230060011Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-?-lactamase inhibitors.Type: ApplicationFiled: September 16, 2022Publication date: February 23, 2023Inventors: Ian Cooper, David Orr, Andrew Wilkinson, Jonathan Finlayson, Adam Bunt, Pia Appelqvist, Hans Wallberg, Fredrik Wångsell
-
Publication number: 20230018460Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-?-lactamase inhibitors.Type: ApplicationFiled: November 19, 2020Publication date: January 19, 2023Inventors: Andrew Wilkinson, Ian Cooper, David Orr, Jonathan Finlayson, Adam Bunt, Pia Appelqvist, Hans Wallberg, Fredrik Wångsell, James Kirkham
-
Patent number: 11459296Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-?-lactamase inhibitors.Type: GrantFiled: May 16, 2019Date of Patent: October 4, 2022Assignee: INFEX Therapeutics LimitedInventors: Ian Cooper, David Orr, Andrew Wilkinson, Jonathan Finlayson, Adam Bunt, Pia Appelqvist, Hans Wallberg, Fredrik Wångsell
-
Publication number: 20210230115Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-?-lactamase inhibitors.Type: ApplicationFiled: May 16, 2019Publication date: July 29, 2021Inventors: Ian Cooper, David ORR, Andrew Wilkinson, Jonathan Finlayson, Adam Bunt, Pia Appelqvist, Hans Wallberg, Fredrik Wångsell
-
Patent number: 10172846Abstract: Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.Type: GrantFiled: March 27, 2017Date of Patent: January 8, 2019Assignee: Medivir ABInventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
-
Publication number: 20170196849Abstract: Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.Type: ApplicationFiled: March 27, 2017Publication date: July 13, 2017Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
-
Patent number: 8338471Abstract: The invention provides compounds of the formula (I) wherein the variables are as defined in the specification. The compounds of the invention are inhibitors of metalloproteinase MMP-12 and are among other things useful for the treatment of obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD).Type: GrantFiled: August 31, 2011Date of Patent: December 25, 2012Assignee: Medivir ABInventors: Hans Wallberg, Ming-Hua Xu, Guo-Qiang Lin, Xin-Sheng Lei, Piaoyang Sun, Kevin Parkes, Tony Johnson, Bertil Samuelsson
-
Publication number: 20120015994Abstract: The invention provides compounds of the formula (I) wherein the variables are as defined in the specification. The compounds of the invention are inhibitors of metalloproteinase MMP-12 and are among other things useful for the treatment of obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: August 31, 2011Publication date: January 19, 2012Applicant: Medivir ABInventors: Hans WALLBERG, Ming-Hua Xu, Guo-Qiang Lin, Xin-Sheng Lei, Piaoyang Sun, Kevin Parkes, Tony Johnson, Bertil Samuelsson
-
Patent number: 8022092Abstract: The invention provides compounds of the formula (I) wherein the variables are as defined in the specification. The compounds of the invention are inhibitors of metalloproteinase MMP-12 and are among other things useful for the treatment of obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD).Type: GrantFiled: December 13, 2006Date of Patent: September 20, 2011Assignee: Medivir ABInventors: Hans Wallberg, Ming-Hua Xu, Guo-Qiang Lin, Xin-Sheng Lei, Piaoyang Sun, Kevin Parkes, Tony Johnson, Bertil Samuelsson
-
Patent number: 7807677Abstract: Compounds of the formula I: wherein R1, R2, X and N are as defined in the specification; E is N, CH; A? and A? are terminal groups as defined in the specification. The compounds have utility as HIV-1 protease inhibitors.Type: GrantFiled: February 9, 2006Date of Patent: October 5, 2010Assignee: Medivir ABInventors: Jenny Ekegren, Anders Hallberg, Hans Wallberg, Bertil Samuelsson, Mahalingam Kannan
-
Publication number: 20100166706Abstract: Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.Type: ApplicationFiled: December 21, 2009Publication date: July 1, 2010Applicant: Medivir ABInventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
-
Patent number: 7671032Abstract: Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.Type: GrantFiled: January 28, 2005Date of Patent: March 2, 2010Assignee: Medivir ABInventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
-
Publication number: 20090215846Abstract: The invention provides compounds of the formula (I) wherein the variables are as defined in the specification. The compounds of the invention are inhibitors of metalloproteinase MMP-12 and are among other things useful for the treatment of obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: December 13, 2006Publication date: August 27, 2009Applicant: Medivir ABInventors: Hans Wallberg, Ming-Hua Xu, Guo-Qiang Lin, Xin-Sheng Lei, Piaoyang Sun, Kevin Parkes, Tony Johnson, Bertil Samuelsson
-
Publication number: 20080249102Abstract: Compounds of the formula I: wherein R1, R2, X and N are as defined in the specification; E is N, CH; A? and A? are terminal groups as defined in the specification. The compounds have utility as HIV-1 protease inhibitors.Type: ApplicationFiled: February 9, 2006Publication date: October 9, 2008Inventors: Jenny Ekegren, Anders Hallberg, Hans Wallberg, Bertil Samuelsson, Mahalingam Kannan
-
Patent number: 7405310Abstract: This invention relates to non-nucleoside reverse transcriptase inhibitors active against HIV-1 and having an improved resistance and pharmacokinetic profile. The invention further relates to novel intermediates in the synthesis of such compounds and the use of the compounds in antiviral methods and compositions.Type: GrantFiled: March 2, 2005Date of Patent: July 29, 2008Assignee: Medivir ABInventors: Stefan Lindstrom, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Oden, Lotta Naeslund
-
Publication number: 20070203072Abstract: Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.Type: ApplicationFiled: January 28, 2005Publication date: August 30, 2007Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
-
Publication number: 20050240035Abstract: This invention relates to non-nucleoside reverse transcriptase inhibitors active against HIV-1 and having an improved resistance and pharmacokinetic profile. The invention further relates to novel intermediates in the synthesis of such compounds and the use of the compounds in antiviral methods and compositions.Type: ApplicationFiled: March 2, 2005Publication date: October 27, 2005Applicant: Medivir ABInventors: Stefan Lindstrom, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Oden, Lotta Naeslund
-
Patent number: 6894177Abstract: Compounds of the formula I: where; R1 is O, S; R2 is an optionally substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)urea bond; R3 is H, C1-C3 alkyl, R4-R7 are independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, haloC1-C6 alkyl, C1-C6 alkanoyl, haloC1-C6 alkanoyl, C1-C6 alkoxy, haloC1-C6 alkoxy, C1-C6 alkyloxy-C1-C6 alkyl, haloC1-C6 alkyloxy-C1-C6 alkyl hydroxy-C1-C6 alkyl, amino-C1-C6 alkyl, carboxy-C1-C6 alkyl, cyano-C1-C6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto; X is —(CH2)n?—D—(CH2)m—; D is —O—, —S—; n and m are independently 0 or 1; and prodrugs and pharmaceutically acceptable salts thereof, have utility as inhibitors of HIV-1 reverse transcriptase, particularly drug escape mutants.Type: GrantFiled: February 28, 2003Date of Patent: May 17, 2005Assignee: Medivir ABInventors: Stefan Lindström, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Odén, Lotta Naeslund
-
Patent number: 6716850Abstract: Compounds of the formula I: where; R1 is O, S; R2 is an optionally substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)urea bond; R3 is H, C1-C3 alkyl, R4-R7 are independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, haloC1-C6 alkyl, C1-C6 alkanoyl, haloC1-C6 alkanoyl, C1-C6 alkoxy, haloC1-C6 alkoxy, C1-C6 alkyloxy-C1-C6 alkyl, haloC1-C6 alkyloxy-C1-C6 alkyl hydroxy-C1-C6 alkyl, amino-C1-C6 alkyl, carboxy-C1-C6 alkyl, cyano-C1-C6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto; X is —(CHR8)n-—D—(CHR8)m—; D is —NR9—, —O—, —S—, —S(═O)— or —S(═O)2—; R8 is independently H, C1-C3 alkyl, halo substitutedC1-C3alkyl; R9 is H, C1-C3 alkyl; n and m are independently 0, 1 or 2; and prodrugs and pharmaceutically acceptable salts thereof, have utility as inhibitors of HIV-1 reverse transcriptase, particularType: GrantFiled: March 5, 2002Date of Patent: April 6, 2004Assignee: Medivir ABInventors: Stefan Lindström, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Odén, Lotta Naeslund